Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Publications found: 10,876
Sort by:

Epclusa- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Epclusa ...

January 2019 35 pages

Esbriet- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Esbriet ...

January 2019 35 pages

Eucrisa- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Eucrisa ...

January 2019 35 pages

Exondys 51- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Exondys ...

January 2019 35 pages

Farxiga- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Farxiga ...

January 2019 35 pages

Farydak- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Farydak ...

January 2019 35 pages

Gazyva- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Gazyva ...

January 2019 35 pages

Genvoya- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Genvoya ...

January 2019 35 pages

Harvoni- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Harvoni ...

January 2019 35 pages

Hetlioz- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Hetlioz ...

January 2019 35 pages

Ibrance- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Ibrance ...

January 2019 35 pages

Imbruvica- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Imbruvica ...

January 2019 35 pages

Ingrezza- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Ingrezza ...

January 2019 35 pages

Invega Sustenna/Xeplion- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Invega Sustenna/Xeplion ...

January 2019 35 pages

Invokana- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Invokana ...

January 2019 35 pages

Jardiance- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Jardiance ...

January 2019 35 pages

Jublia- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Jublia ...

January 2019 35 pages

Kadcyla- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kadcyla ...

January 2019 35 pages

Kanuma- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kanuma ...

January 2019 35 pages

Kengreal- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kengreal ...

January 2019 35 pages

Kevzara- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kevzara ...

January 2019 35 pages

Keytruda- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Keytruda ...

January 2019 35 pages

Kisqali- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kisqali ...

January 2019 35 pages

Kybella- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kybella ...

January 2019 35 pages

Kynamro- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kynamro ...

January 2019 35 pages

Lartruvo- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lartruvo ...

January 2019 35 pages

Lenvima- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lenvima ...

January 2019 35 pages

Lonsurf- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lonsurf ...

January 2019 35 pages

Lovenox- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lovenox ...

January 2019 35 pages

Luzu- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Luzu ...

January 2019 35 pages

Lynparza- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lynparza ...

January 2019 35 pages

Mekinist- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Mekinist ...

January 2019 35 pages

Movantik- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Movantik ...

January 2019 35 pages

Myalept- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Myalept ...

January 2019 35 pages

Natpara- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Natpara ...

January 2019 35 pages

Ninlaro- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Ninlaro ...

January 2019 35 pages

Northera- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Northera ...

January 2019 35 pages

Nucala- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nucala ...

January 2019 35 pages

Nuplazid- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nuplazid ...

January 2019 35 pages

Ocaliva- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Ocaliva ...

January 2019 35 pages

Ofev- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Ofev ...

January 2019 35 pages

Olysio- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Olysio ...

January 2019 35 pages

Opdivo- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Opdivo ...

January 2019 35 pages

Opsumit- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Opsumit ...

January 2019 35 pages

Orbactiv- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Orbactiv ...

January 2019 35 pages

Orkambi- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Orkambi ...

January 2019 35 pages

Osphena- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Osphena ...

January 2019 35 pages

Otezla- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Otezla ...

January 2019 35 pages

Pomalyst- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Pomalyst ...

January 2019 35 pages

Portrazza- Drug Insight, 2019

US$ 1,000.00

... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Portrazza ...

January 2019 35 pages

Filters

Search

Publishers

1
450
353
174
29
4
837
409
36
27
2,279
77
19
16
2
21
1
16
1
9
9
2,264
5
4
31
6
142
1
17
15
248
651
91
1
373
26
34
724
1
2
16
6
4
84
36
3
4
2
7
15
53
16
26
83
11
32
8
2
17
106
27
19
4
7
3
324
15
1
23
86
24
28
44
296
17
18
2

Regions

131
40
38
37
37
35
32
23
13
10
10
9
9
8
8
8
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
6
6
6
6
6
6
5
5
5
5
4
4
3
3
3
3
3
91
12
354
30
6
6
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
2
2
39
6
4
3
3
3
1
1
3
7
9,529

Price

—

Date

—

Pages

—

Offers

9
1